MedTrace Logo

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

NCT00169468 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-08-23

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the response rate and toxicity of the association R-CHOP with two schedules of administration of Velcade, in B-cell CD 20 + lymphoma patients, aged from 18 to 80 years

The goal is to get a response rate at least at what observed with R-CHOP alone and will be evaluates with a sequential test.

The other objective is to evaluate the toxicity

Conditions

  • B Cell Lymphoma

Interventions

DRUG

Rituximab -CHOP plus Velcade

Sponsors & Collaborators

  • Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie

    collaborator OTHER

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • christian Gisselbrecht, MD PHD · Lymphoma Study Association

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169468 on ClinicalTrials.gov